Rituximab-Resistant Nephrotic Syndrome With Successful Induction of Remission by Low-Density Lipoprotein Apheresis

Therapeutic Apheresis and Dialysis

Volumn 21, Issue 3, 2017, Pages 295-296

  Suzuki, Hiroyuki ^a   Tsukamoto, Tatsuo ^a   Muso, Eri ^a  

^a Kitano Hospital   (Japan)

Author keywords

low density lipoprotein apheresis; minimal change nephrotic syndrome; rituximab

Indexed keywords

CD20 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIZORIBINE; PREDNISOLONE; RITUXIMAB; TACROLIMUS; IMMUNOLOGIC FACTOR; LOW DENSITY LIPOPROTEIN;

ADULT; APHERESIS; CASE REPORT; DRUG PULSE THERAPY; FEMALE; HOSPITAL ADMISSION; HUMAN; LETTER; LOW DENSITY LIPOPROTEIN APHERESIS; MINIMAL CHANGE NEPHROTIC SYNDROME; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; RELAPSE; REMISSION; TREATMENT RESPONSE; YOUNG ADULT; BLOOD; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

BLOOD COMPONENT REMOVAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LIPOPROTEINS, LDL; NEPHROTIC SYNDROME; REMISSION INDUCTION; RITUXIMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85021312794     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12561     Document Type: Letter

References (3)

1. Vuong TD, Stroes ES, Willekes-Koolschijn N et al. Hypoalbuminemia increases lysophosphatidylcholine in low-density lipoprotein of normocholesterolemic subjects. Kidney Int 1999;55:1005–1010.
2. Matsumoto K. Decreased release of IL-10 by monocytes from patients with lipoid nephrosis. Clin Exp Immunol 1995;102:603–607.
3. Muso E. Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin Exp Nephrol 2014;18:286–290.